Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies (TSHA) has announced the granting of stock options to three new employees as inducement awards. The Compensation Committee approved options to purchase a total of 491,000 shares of common stock under the company's 2023 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options were granted at an exercise price of $1.53, matching the closing price on the grant date. These options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting in equal monthly installments over the following 36 months. Vesting is contingent upon continued employment with Taysha.
Taysha Gene Therapies (TSHA) ha annunciato l'assegnazione di opzioni su azioni a tre nuovi dipendenti come premi di incentivazione. Il Comitato Compensi ha approvato opzioni per acquistare un totale di 491.000 azioni di azioni ordinarie nell'ambito del Piano di Incentivazione 2023 dell'azienda, in conformità con la Regola di Listaggio Nasdaq 5635(c)(4).
Le opzioni su azioni sono state concesse a un prezzo di esercizio di $1,53, corrispondente al prezzo di chiusura alla data di concessione. Queste opzioni hanno una durata di 10 anni e matureranno in un periodo di quattro anni, con il 25% che matura dopo il primo anno e il restante 75% che matura in rate mensili uguali nei successivi 36 mesi. La maturazione è subordinata al mantenimento dell'impiego con Taysha.
Taysha Gene Therapies (TSHA) ha anunciado la concesión de opciones sobre acciones a tres nuevos empleados como premios de incentivo. El Comité de Compensación aprobó opciones para comprar un total de 491,000 acciones de acciones comunes bajo el Plan de Incentivo 2023 de la empresa, de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq.
Las opciones sobre acciones se otorgaron a un precio de ejercicio de $1.53, coincidiendo con el precio de cierre en la fecha de concesión. Estas opciones tienen un plazo de 10 años y se otorgarán durante un período de cuatro años, con el 25% al finalizar el primer año y el restante 75% en cuotas mensuales iguales durante los siguientes 36 meses. La concesión está sujeta a la continuidad del empleo con Taysha.
Taysha Gene Therapies (TSHA)는 세 명의 새로운 직원에게 유인 보상으로 주식 매수 옵션을 부여한다고 발표했습니다. 보상위원회는 회사의 2023년 유인 계획에 따라 491,000주의 보통주를 구매할 수 있는 옵션을 승인했습니다. 이는 나스닥 상장 규칙 5635(c)(4)에 따른 것입니다.
주식 옵션은 부여일의 종가에 해당하는 $1.53의 행사 가격으로 부여되었습니다. 이 옵션은 10년간 유효하며, 4년에 걸쳐 부여되어 첫 해에 25%가 부여되고 나머지 75%는 다음 36개월간 매달 균등하게 부여됩니다. 부여는 Taysha에서 계속 근무하는 조건입니다.
Taysha Gene Therapies (TSHA) a annoncé l'octroi d'options d'achat d'actions à trois nouveaux employés dans le cadre de récompenses d'incitation. Le Comité de Rémunération a approuvé des options pour l'achat d'un total de 491 000 actions ordinaires dans le cadre du Plan d'Incitation 2023 de l'entreprise, conformément à la Règle de Cotation 5635(c)(4) de Nasdaq.
Les options d'achat d'actions ont été attribuées à un prix d'exercice de $1,53, correspondant au prix de clôture à la date d'attribution. Ces options ont une durée de 10 ans et seront acquises sur une période de quatre ans, avec 25 % acquises après la première année et les 75 % restantes acquises en versements mensuels égaux répartis sur les 36 mois suivants. L'acquisition est soumise à la poursuite de l'emploi avec Taysha.
Taysha Gene Therapies (TSHA) hat die Gewährung von Aktienoptionen an drei neue Mitarbeiter als Anreizpreise bekannt gegeben. Der Vergütungsausschuss genehmigte Optionen zum Kauf von insgesamt 491.000 Aktien im Rahmen des Unternehmensplans für Anreize 2023, in Übereinstimmung mit der Nasdaq-Zulassungsregel 5635(c)(4).
Die Aktienoptionen wurden zu einem Ausübungspreis von $1,53 gewährt, was dem Schlusskurs am Tag der Gewährung entspricht. Diese Optionen haben eine Laufzeit von 10 Jahren und werden über vier Jahre fällig, wobei 25 % nach dem ersten Jahr fällig werden und die verbleibenden 75 % in gleichen monatlichen Raten über die nächsten 36 Monate fällig werden. Die Fälligkeit ist an eine fortgesetzte Anstellung bei Taysha gebunden.
- Stock options grant demonstrates ability to attract new talent
- Four-year vesting schedule promotes employee retention
- Potential future dilution for existing shareholders from 491,000 new stock options
DALLAS, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on February 3, 2025, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 491,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has an exercise price of
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com
FAQ
How many shares were granted in TSHA's February 2025 inducement awards?
What is the exercise price for TSHA's February 2025 stock option grants?
What is the vesting schedule for TSHA's February 2025 inducement stock options?
How long is the term of TSHA's February 2025 inducement stock options?
